Clinical Trials Logo

Relapsed Neuroblastoma clinical trials

View clinical trials related to Relapsed Neuroblastoma.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03649438 No longer available - Clinical trials for Relapsed Neuroblastoma

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.